直接抗病毒药物治疗慢性丙型肝炎48周临床观察

表3 基线与直接抗病毒药物治疗结束及随访12 wk、48 wk肝功能变化及复常率

指标	基线, n = 145	治疗结束, n = 143	12 wk, n = 133	48 wk, n = 131
ALT	69 (10-819); 49.7% (71/143)	26 (4-148); 90.9% (130/143)a	17 (3-103); 92.5% (123/133)a	21 (2-110); 93.2% (124/133)a
AST	42 (10-735); 50.0% (70/143)	32 (10-102); 88.9% (127/143)a	22 (8-79); 90.0% (120/133)a	22 (10-79); 91.7% (122/133)a
ALP	95 (19-289); 86.0% (117/136)	83 (18-167); 87.5% (126/144)	70 (37-175); 94.7% (125/132)a	72 (16-156); 97.7% (130/133)a
GGT	50 (11-936); 55.9% (76/136)	23 (8-141); 91.0% (131/144)a	21 (4-145); 86.4% (114/132)a	21 (7-127); 88.7% (118/133)a
TBIL	17 (5-55); 65.2% (90/138)	15 (5-57); 69.6% (96/138)	13 (4-40); 73.0% (96/132)	14 (4-52); 73.3% (96/131)
ALB	46 (32-55); 96.3% (130/135)	47 (31-554); 97% (131/135)	48 (34-55); 97.7% (129/132)	48 (24-56); 97.7% (129/132)
Cr	63 (40-964); 91.8% (123/134)	64 (39-1075); 92.5% (124/134)	65.5 (40-966); 89.8% (106/118)	66 (38-946); 99.1% (111/112)a

^aP<0.05. ALT: 丙氨酸氨基转移酶; AST: 天冬氨酸氨基转移酶; ALP: 碱性磷酸酶; GGT: 谷氨酰转肽酶; TBIL: 总胆红素; ALB: 白蛋白.